mRNA-Based Therapeutics Summit mRNA on July 20-22, 2026 in Boston, United States

From recent acquisitions - including Eli Lilly and Orna, BMS and Orbital, AbbVie and Capstan and BioNTech and CureVac - the mRNA landscape is evolving fast, with assets in in vivo CAR-T, gene editing, and cancer immunotherapies advancing toward clinical validation and potential commercial reality.

With science innovation at the core of the momentum, the 6th mRNA‑Based Therapeutics Summit returns to Boston this summer as the world's flagship meeting for the mRNA community. Bringing together 350+ global leaders - from pharma powerhouses to trailblazing biotech start-ups including Moderna, Pfizer, AstraZeneca, Sanofi, ParcelBio, CaVos Therapeutics, Kernal Biologics and more - the summit delivers exclusive breakthroughs, strategic insights, and collaboration opportunities that are shaping the conversation and future of mRNA technology.

With a revitalized three-track agenda covering Discovery, Pre-Clinical and Clinical Development, and Manufacturing and CMC, plus two brand-new focus days on AI-Driven mRNA Design and Next-Gen Delivery Technologies, this forum reaffirms its position as the go-to hub for uniting top decision makers, showcasing scientific excellence, partnership building, and pipeline acceleration.

Join with your peers and power the next wave of mRNA therapies and tools to combat all diseases.

URLs:

Tickets: https://go.evvnt.com/3498454-2?pid=10008

Brochure: https://go.evvnt.com/3498454-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Conference + AI or Delivery Day - Drug Developer : USD 4397.00,

Conference Only - Drug Developer : USD 3099.00,

Conference + AI or Delivery Day - Academia, Biotech Start-Up and Investor Pricing: USD 3797.00,

Conference Only - Academia, Biotech Start-Up and Investor Pricing: USD 2699.00,

Conference + AI or Delivery Day - Service Provider Pricing : USD 5297.00,

Conference Only - Service Provider Pricing : USD 3799.00

Speakers: George Thom, Director of RNA Therapeutics, AstraZeneca, Christine Tkaczyk, Director of Early Vaccines and Immune Therapies, AstraZeneca, Bei Cheng, Associate Principal Scientist, AstraZeneca, Alex Zinoviev, Director, mRNA Platform, Eli Lilly, Brian Friedrich, Associate Director of Analytical Development, Genentech, Alan Enciso, Principal Scientist, GSK, Ruchi Shah, Head US Drug Product, Vaccines Technical R and D, GSK, Julia Lee, Senior Director of Search and Evaluation – Vaccines and ID, GSK, Matt Schmidt, Director of Third-Party Quality Management, Merck and Co, Vikram Agarwal, Head of mRNA Platform Design Data Science, mRNA Center of Excellence, Sanofi, Yimin Hua, Head of Biochemistry and Biophysics, US Analytical Development, mRNA Centre of Excellence, Sanofi, Nikhil Adi, Senior Principal Scientist, Pfizer, Sizhen Li, Computational Science Lead, Sanofi, Saswata Karmakar, Director of Discovery Chemistry, mRNA Centre of Excellence, Sanofi, Christina Vorvis, Director, Abbvie Ventures, Marco Cavaleri, Head of Biological Health Threats and Vaccine Strategy, European Medicines Agency, David Kolesky, Principal, MPM Capital, Iain McFadyen, Fractional Chief AI Officer, Abogen Biosciences, Cory Sago, Chief Executive Officer, Amplitude Therapeutics, Ahmet Can Berkyurek, Chief Executive Officer and Co-founder, Cambridge Medixine, Haim Belinson, Chief Executive Officer, CaVos Biotherapeutics, Ajay Gupta, Chief Executive Officer, Celestial Therapeutics, Peter Weinstein, Chief Executive Officer, Circurna, Daniel Getts, Chief Executive Officer, CREATE Medicines, Carsten Rudolph, Chief Executive Officer, Ethris, Nikola Ivica, Co-founder and Chief Scientific Officer, InnDura Therapeutics, Joshua McGee, Chief Scientific Officer and Co-Founder, Keylicon Biosciences, Roger Adami, Chief Technology Officer, Land Therapeutics, Randall Hyer, Chief Executive Officer, Merlin Biotech, Ali Nahvi, Chief Technology Officer, Nava Therapeutics, David Weinberg, Chief Executive Officer, Parcelbio, Timothy Day, Co- Founder and Chief Scientific Officer, Particella, Natalia Martin, Orozco Chief Scientific Officer, Providence Therapeutics, Nathaniel Wang, Chief Executive Officer, Replicate Bioscience, Kathy Fernando, Chief Business Officer, Replicate Bioscience, Yoon Ki Kim, Chief Technology Officer and Professor, RiboTech and Korea Advanced Institute of Science and Technology, Priya Mande, Chief Executive Officer, RNAvate, Prashant Nambiar, Chief Scientific Officer, Strand Therapeutics, Yingzhong Li, President, SunVax mRNA Therapeutics, Jason Zhang, Chief Executive Officer, Zipcode Bio, Abhijeet Pataskar, Group Leader, BioNTech, Akshay Phulgirkar, Senior Manager, Moderna, Amit Singh, Vice President of Platform, Mote Therapeutics, Chijan Zuo, Vice President of R and D, CureMed Biopharma, David Thompson, Professor, Purdue University, Eduardo Eyras, Director, Shine-Dalgarno Centre for RNA Innovation and Professor, EMBL-Australia Group Leader, Australian National University, Fabio Rosa, Co-founder, Head Of Research and Board Observer, Asgard Therapeutics, Hela Kallel, CMC Technology lead, CEPI, Jeff Ozdemir, Co-Founder and Head of Platform, Kernal Biologics, Jian Ding, Vice President of Translational Research, CREATE Medicines, Krishna Sapkota, Senior Scientist, Beam Therapeutics, Kui Wang, Director, Verve Therapeutics, Michael Evangelopoulos, Business Development Manager, Flashpoint Therapeutics, Michael Mingueneau, Vice President and Head of Immunology, Sail Bio, Poulami Talukder, Principal Scientist, Tiba Biotech, Rajesh Krishnan, Vice President of Delivery Technology and Development, Providence Therapeutics, Sai Prathyusha, Bhamidipati Director of Regulatory CMC, Moderna, Sara Ali, Computation Scientist, Moderna, Syed Ali, Principal Scientist, Moderna, Taesun Eom, Director of Rna Technologies, nChromaBio, Yutaka Saito, Professor, Kitasato University, National Institute of Advanced Industrial Science and Technology, Anmol Seth, AI Design Lead, Eclipsebio, May Guo, Strategic Consultant, Vazyme Biotech, Victoria Marshall, Rsearcher, Beacon, Wayne Doyle, Head of Scientific Platforms and Strategy, Eclipsebio